Novavax
FILE PHOTO: Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Novavax Inc said on Wednesday (May 4) it had filed an application with The Medicines and Healthcare products Regulatory Agency for the authorisation of its Covid-19 vaccine among adolescents aged 12 and older.

The medicines regulator had in February cleared the two-dose vaccine, Nuvaxovid, for use in adults amid a spike in cases fuelled by the Omicron variant of the coronavirus.

Novavax’s submission includes data from a late-stage trial in the United States, where the vaccine showed 80 per cent efficacy among adolescents when Delta was the dominant variant in the country.

The drugmaker in late January filed for emergency use authorisation of its Covid-19 shot for adults in the United States.

The U.S. Food and Drug Administration plans to hold several meetings of its outside panel of experts in June to discuss authorisation requests submitted by multiple Covid-19 vaccine manufacturers including Novavax.

If you want to share your stories and/or experiences with us, please send an email to [email protected]

LEAVE A REPLY